Indication present: surgery need not wait for antibiotics to finish. Delay can be dire; in general illness is not a limit (AHA 2015 Class I, LOE B). No hour or day is established in children. Pediatric, no hour or day tested. Khoo 2019, 138 operated: risk of death rose slightly with each preoperative antibiotic day (HR 1.02, 95% CI 1.00–1.03, p=.009) and surgery in the active phase did not raise death or reoperation; the authors suggest surgery within 3 days of diagnosis when indicated. Confounded: surgical patients only, and the authors say right-sided disease failing medical therapy may explain it. Lee 2021, 9 early vs 36 later, small: no significant difference in survival, recurrence or reoperation; early was within 2 days left-sided, within 7 days right-sided; median 3 vs 20.5 days; 5 diagnosed during surgery left out. Shamszad 2013: of 46 operated, 35 within 7 days and 25 within 3 days, no postoperative septic embolization; not a comparison of timing. PAC3 2025: ideal timing not defined. Not yet stabilized: waiting may allow stabilization but risks valve destruction, abscess, heart block, emboli and death (Lee 2021, opinion); no source read tests it. Preoperative shock carried higher death in two overlapping Melbourne series, neither testing delay: HR 3.68 (95% CI 1.15–11.7; Khoo 2019), 6.4 (1.3–32.0; Wu 2023 abscess). Adult ESC 2023: emergency within 24 h, urgent within 3–5 days, non-urgent within the same admission. Adult ACC/AHA 2020 "early": during the first hospitalization, before a full antibiotic course, no hours or days. Adult AATS 2016: once indicated, within days (I, B); emergency or within 48 h for large mobile vegetations at imminent risk (IIa, B).
Stroke or intracranial hemorrhage can change the timing: Stroke timing (Adult; no pediatric data).
A negative echo does not exclude endocarditis (JCS 2026; ESC 2023, CHD). Valve and conduit rows.
What to start · Vegetation size · Repair or replacement
| How soon to operate | Indication | Class by source |
|---|---|---|
| Heart failure | ||
| Emergency Adultwithin 24 h | Cardiogenic shock from acute severe valve dysfunction or shunt, severe pulmonary edema, or new severe heart failure symptoms | Pediatric AHA 2015 listed, no class · PAC3 2025 Moderate / StrongAdult JCS 2026 · ESC 2023 I B · ACC/AHA 2020 I B-NR |
| Urgent Adultwithin several days | Heart failure symptoms (PAC3); acute aortic or mitral regurgitation with ventricular failure, or unresponsive heart failure (AHA 2015 Table 11). Adult JCS also: severe regurgitation, worsening hemodynamics on echo, at least moderate pulmonary hypertension | Pediatric AHA 2015 listed, no class · PAC3 2025 Moderate / StrongAdult JCS 2026 · ESC 2023 I B · ACC/AHA 2020 I B-NR |
| Uncontrolled infection | ||
| Emergency or urgent Adultwithin 24 h to several days | Abscess, pseudoaneurysm, intracardiac shunt, enlarging vegetation, or new AV block or LBBB ESC 2023: urgent, not emergency; also names fistula and prosthetic dehiscence. | Pediatric AHA 2015 named, no class · PAC3 2025 Moderate / StrongAdult JCS 2026 · ESC 2023 I B · ACC/AHA 2020 I B-NR |
| Emergency or urgent Adultwithin 24 h to several days | Sepsis affecting hemodynamics despite appropriate therapy ESC 2023: persistent sepsis despite antibiotics and adequate control of metastatic foci, urgent, should be considered. | Pediatric no class givenAdult JCS 2026 I B · ESC 2023 IIa B |
| Urgent or elective Adultwithin several days, or 1–2 wk after antibiotics | Fungi, S. aureus or other resistant organisms such as MRSA or VRE, or a needed change of antibiotic JCS 2026 urgency names fungi and highly resistant bacteria only; ESC 2023: urgent or non-urgent by hemodynamics. PAC3 names abscess, change of antibiotic, S. aureus, fungal or other resistant organisms and heart failure. ACC/AHA names left-sided S. aureus. AHA 2015 is for fungal disease, with an exception for neonates with mural endocarditis and occasional older children, and early consultation with infectious diseases, cardiology and cardiac surgery. | Pediatric AHA 2015 I C, fungal only · PAC3 2025 Moderate / StrongAdult JCS 2026 · ESC 2023 I C · ACC/AHA 2020 I B-NR |
| Urgent Adultwithin several days | Persisting infection on appropriate therapy, no other focus. Adult JCS: typically positive cultures or clinical findings at 3–5 days Adult. ACC/AHA 2020: bacteremia or fever beyond 5 days. AATS 2016: beyond 5–7 days (I, B). ESC 2023: positive cultures beyond 1 week. | Pediatric AHA 2015 named, no classAdult JCS 2026 · ESC 2023 IIa B · ACC/AHA 2020 I B-NR |
| Urgent or elective Adultwithin several days, or 1–2 wk after antibiotics | Prosthetic valve: relapse or recurrence AHA 2015: relapsing, even with intact valve function. ACC/AHA: relapse with no other source. | Pediatric AHA 2015 IIb BAdult JCS 2026 IIa C · ACC/AHA 2020 I C-LD |
| Urgent or elective Adultwithin several days, or 1–2 wk after antibiotics | Prosthetic valve: S. aureus, resistant staphylococci or non-HACEK Gram-negative organisms JCS 2026 names resistant staphylococci; ESC 2023 names S. aureus, urgent, should be considered. | Pediatric AHA 2015 IIb C, S. aureusAdult JCS 2026 · ESC 2023 IIa C |
| Not timed by name; a shunt or heart failure takes those rows | Unstable prosthesis, ruptured sinus of Valsalva, ventricular septal or mycotic aneurysm Mycotic aneurysm: for rupture risk. JCS 2026 pediatric section also names prosthetic valve or conduit dysfunction. | Pediatric AHA 2015 named, no class; mycotic aneurysm IIb B · JCS 2026 named, no class |
| Embolism | ||
| Urgent Adultwithin several days | Embolic event with a vegetation persisting or enlarging on therapy. Adult JCS: >10 mm; ESC: ≥10 mm. PAC3: recurrent embolism or recanalized septal defect, no size. ACC/AHA: recurrent emboli with persistent vegetations, no size. AHA 2015 Table 11 lists embolic events and persistent vegetation after embolization, no size, no class. JCS 2026 pediatric section names embolic events, no size. AATS 2016, Adult: mobile >10 mm with embolic phenomena despite therapy, urgent or emergency may be considered, IIb, B. | Pediatric AHA 2015 listed, no class · PAC3 2025 Low / WeakAdult JCS 2026 · ESC 2023 I B · ACC/AHA 2020 IIa B-NR |
| Urgent Adultwithin several days | Progressive valve dysfunction. Adult JCS: with mobile >10 mm; ESC: ≥10 mm with another indication. | Pediatric JCS 2026 named, no classAdult JCS 2026 I B · ESC 2023 I C |
| Urgent, Adult only Adultwithin several days | Vegetation alone, to prevent a first embolus: mobile >10 mm, no other indicationPediatric: not recommended: no proven benefit, long-term risks of valve replacement (AHA 2015 Class III, LOE C). Same statement, Table 11, a 1998 adult reprint: anterior mitral leaflet, particularly >10 mm, may need surgery. JCS adds low surgical risk; ACC/AHA is native left-sided, with or without embolism; ESC is aortic or mitral, ≥10 mm, without severe dysfunction or without embolism, low surgical risk. AHA 2015 p 1507 also notes adult data at >10 mm and one supporting pediatric study. | Pediatric AHA 2015 III CAdult JCS 2026 IIb C · ESC 2023 IIb B · ACC/AHA 2020 IIb B-NR |
Vegetation alone: the classes differ. Pediatric AHA 2015: surgery to prevent a first embolus is Class III, LOE C. Adult mobile >10 mm: JCS 2026 IIb, C; ACC/AHA 2020 IIb, B-NR; ≥10 mm: ESC 2023 IIb, B. Size alone is hard to interpret in a small child: even 5 mm may matter on a newborn's mitral valve (Backer 5e ch 45 pp 962–963 textbook, opinion). JCS 2026: no clear pediatric data on surgical indications to prevent embolism.
Any row: cardiology, surgery and infectious diseases review every admitted patient, ongoing, to choose medical or surgical care and its timing, including shortening preoperative antibiotics when appropriate (PAC3 High / Strong). Consider early surgery, especially if repair is an option (PAC3 Moderate / Strong). S. aureus: care where there is cardiac surgery and infectious diseases (AHA 2015 Class I, LOE C). Adult AHA 2026: within 48–72 h once indicated, unless major stroke or cerebral hemorrhage.
| Finding | What the source says | Class by source |
|---|---|---|
| TPVR, RV-PA conduit or pulmonary bioprosthesis | ||
| Mild and stable | Definite or possible right-sided endocarditis after TPVR, mild symptoms, mild prosthetic dysfunction, no hemodynamic compromise: favor medical therapy PAC3 p 2435: about half managed without surgical valve replacement in a multicenter cohort; sepsis or severe RV dysfunction carried higher mortality. | Pediatric PAC3 2025 Moderate / Strong |
| S. aureus | After TPVR: consider early surgical explantAll organisms 27–64% by center; streptococcus 32%, MSSA 53%, MRSA all (Davtyan 2022 abstract). No comparison of explant against medical treatment. | Pediatric PAC3 2025 Moderate / Strong |
| RVOT gradient | New or increased, no structural cause: count as an extra minor Duke criterion Adult ACHD 2025: endocarditis may cause rapidly progressive conduit stenosis. | Pediatric PAC3 2025 High / Strong |
| Modified Duke not met | RV-PA conduit or pulmonary bioprosthesis: do not exclude endocarditis for that alone. At least possible endocarditis with nothing on TTE or TEE: pursue ICE, CT or PET/CT | Pediatric PAC3 2025 Very Low / Strong |
| Bovine jugular valve | Consider endocarditis even with negative cultures | Pediatric PAC3 2025 Moderate / Strong |
| Prosthetic material | Shunt or conduit: bacteriologic cure often impossible without surgery; vegetations may cause dehiscence, obstruction or distal emboli | Pediatric AHA 2015 no class |
No pediatric data on how long to wait. Every time here is Adult. PAC3 2025: in children with neurologic complications, evidence supports preoperative neuroimaging and pediatric neurology evaluation, left out of its recommendations as not specific to CHD. High index of suspicion for stroke with left-sided lesions (PAC3 Low / Strong).
| Situation | AHA 2026 | JCS 2026 Table 35 | ACC/AHA 2020 | ESC 2023 Table 17 | AATS 2016 Table 3 |
|---|---|---|---|---|---|
| No hemorrhage, no severe deficit | Small strokes on imaging, no deficit: no delay | Early surgery indicated, no coma or herniation: no delay I B | No hemorrhage or extensive damage: no delay may be considered IIb B-NR | TIA: no delay I B. Stroke with heart failure, uncontrolled infection, abscess or high embolic risk: no delay, if no coma and CT or MRI excludes hemorrhage I B | Non-hemorrhagic with a strong cardiac indication: earlier surgery reasonable IIa B |
| Embolic, no bleeding, unstable or high re-embolism risk | Urgent (<72 h) or emergent surgery should be considered. High risk: large or mobile >10 mm, mitral (especially anterior leaflet), staphylococcal | — | — | The no-delay row above | — |
| Extensive infarct | Take-home point: major ischemic stroke usually at least 2, preferably 4 weeks; its body text ties that delay to hemorrhage | Prognosis not hopeless: after neurologic stabilization and antibiotics IIa C | If hemodynamically stable: delay at least 4 weeks may be considered IIb B-NR | — | Large or multiple strokes, severe symptoms: neurologist first I B |
| Intracranial hemorrhage | Usually at least 2, preferably 4 weeks, by stability and neurologic evaluation | Within 2 weeks once neurologically stable, no hematoma expansion IIa C. With expansion: after at least 4 weeks of antibiotics IIa B | If hemodynamically stable: delay at least 4 weeks may be considered IIb B-NR | Delay beyond 1 month if possible, reassessing often IIa C. Unstable: urgent or emergency should be considered, weighing neurologic outcome IIa C | Recent: delay 3 or more weeks reasonable IIa B |
| Embolic stroke with hemorrhage | Early surgery may be considered in select cases: high re-embolism risk, hemodynamic compromise, sepsis or abscess. Otherwise 3–4 weeks | — | — | — | — |
| Series | Operation, n | Early death | 10-y survival | 10-y free of reoperation |
|---|---|---|---|---|
| Wu 2024 aortic, 41 | Repair, 16 | 0/16 | 87.5% | 30.8% |
| Ross, 13 | 2/13 (15.4%) | 74.1% | 63.0% | |
| Homograft root, 9 | 3/9 (33.3%) | 66.7% | 26.3% | |
| Mechanical, 3 | 1/3 | — | — | |
| Wu 2023 mitral, 39 | Repair, 36 (92.3%) | 2/36 (5.6%) | — | 62.9%; 80.2% free of valve replacement |
| Replacement, 3 | — | — | — |
Wu 2024: survival p>0.05; reoperation, Ross vs repair p=0.15, Ross vs homograft p=0.002.
Figures, in the book: Backer 5e Figs 45.1–45.4 (tricuspid), 45.5–45.13 (aortic), 45.14–45.21 (mitral).
| Population | Rate | Source |
|---|---|---|
| Children with CHD, Quebec, 47,518; cumulative rate from the 34,279 followed since birth | 6.1 per 1000 children by age 18 (5.0–7.5). Against ASD: cyanotic RR 6.44, endocardial cushion 5.47, left-sided 1.88. Surgery within 6 months RR 5.34. Age <3 y RR 3.53, against ages 6–18 | Rushani 2013 |
| Children with CHD, Norway | 2.2 per 10,000 person-years; 8% endocarditis mortality | Jortveit 2018 abstract |
| Tetralogy of Fallot, Denmark, from birth; mixed ages | 22.4 per 10,000 person-years vs 0.1 in controls | Havers-Borgersen 2021 abstract |
| After TPVR, 2476, international registry; mixed ages | 2.2 per 100 patient-years; 9.5% at 5 y, 16.9% at 8 y; median 2.7 y to onset. Younger age, prior endocarditis, higher residual gradient; valve type not a factor on multivariable analysis | McElhinney 2021 |
| Congenital AS, Second Natural History Study | 27.1 per 10,000 person-years; 15.7 managed medically vs 40.9 surgically. Prior valvotomy: the authors read the excess as severity, not the operation. Before balloon valvuloplasty became the usual first step | Gersony 1993 abstract |
Share of cases, not risk. Mostly coded data, not microbiologic confirmation.
Figures, in the book: Lai 3e Figs 41.16 (vegetation on a homograft in an RV-PA conduit), 41.19 (ICE into a Melody valve), 41.11 and 41.14 (ring abscess); Moss 10e Fig 62.2 (neonatal tricuspid vegetations).
Before any dose. Boxed warnings and key contraindications: next box. Other label lines: closed box after it. A drug in neither had no label read. AHA 2015 gives no neonate or infant doses: consult infectious diseases and pediatric clinical pharmacists.
FDA labels. Each drug is contraindicated with known hypersensitivity to it; penicillins and cephalosporins, to any of their class.
| Organism | First choice, daily dose; alternative; duration |
|---|---|
| Unknown organism: native (community), or prosthetic >1 y after surgery | Ampicillin-sulbactam 200–300 mg/kg/d divided every 4–6 h, up to 12 g daily, plus gentamicin 3–6 mg/kg/d divided every 8 h (Adult 3–5), with or without vancomycin 60 mg/kg/d every 6 h, up to 2 g. Prosthetic: add rifampin 15–20 mg/kg/d divided every 12 h, up to 600 mg.Cultures before the first dose. Severely ill and unstable: 3 cultures over 1–2 h, then start (AHA 2015 Class I, LOE C). Not severely ill, cultures still negative: AHA 2015 finds holding antibiotics at least 48 h for more cultures reasonable (Class IIa, LOE C; Class IIb, LOE C in its diagnosis section). ESC 2023 starts promptly after 3 sets at 30-minute intervals. When to start rifampin: sources differ, prosthetic staphylococci row. ESC 2023 Recommendation Table 10, native or prosthetic ≥12 months after surgery (IIa, C): ampicillin 200–300 mg/kg/d in 4–6 doses, up to 12 g/d, with ceftriaxone 100 mg/kg in 1 dose, or with (flu)cloxacillin 200–300 mg/kg/d in 4–6 doses and gentamicin 3 mg/kg/d in 3 doses. Allergic to penicillin (IIb, C): cefazolin 100 mg/kg/d in 3–4 doses, up to 6 g/d, or vancomycin 40 mg/kg/d in 2–3 doses, with gentamicin 3 mg/kg/d in 3 doses.Alternative: vancomycin plus gentamicin. Duration, culture-negative: native 4–6 wk, prosthetic 6 wk. |
| Unknown organism: nosocomial with vascular cannulae, or prosthetic ≤1 y after surgery | Vancomycin 60 mg/kg/d divided every 6 h, up to 2 g, plus gentamicin 3–6 mg/kg/d divided every 8 h (Adult 3–5), with or without rifampin 20 mg/kg/d divided every 8 h, up to 900 mg/d, if prosthetic material; plus cefepime 100–150 mg/kg/d divided every 8–12 h, up to 6 g/d, or ceftazidime 100–150 mg/kg/d divided every 8 h, up to 2–4 g daily.Cultures as in the row above. When to start rifampin: sources differ, prosthetic staphylococci row. ESC 2023 Recommendation Table 10, prosthetic <12 months after surgery or healthcare-associated (IIb, C): vancomycin 40 mg/kg/d in 2–3 doses, gentamicin 3 mg/kg/d in 3 doses, rifampin 20 mg/kg/d in 3 doses, up to 900 mg/d; its text says ideally also cover non-HACEK Gram-negative organisms.Alternative: none given (Table 7 prints a question mark). Duration, culture-negative prosthetic: 6 wk. |
| Streptococci, highly susceptible (MBC ≤0.1 µg/mL) | Penicillin G 200,000–300,000 U/kg/d divided every 4 h, up to 12–24 million U daily, or ceftriaxone 100 mg/kg/d divided every 12 h or 80 mg/kg/d every 24 h, up to 4 g daily (over 2 g, divide twice daily).Alternative: vancomycin 40 mg/kg/d divided every 8–12 h, up to 2 g daily; cefazolin 100 mg/kg/d divided every 8 h, up to 12 g daily; ceftriaxone. Cannot take a β-lactam: vancomycin, with gentamicin as current practice, 4 wk. Prosthetic material and cannot take a β-lactam: vancomycin 6 wk, gentamicin first 2 wk. Duration: native 4 wk; a 2-week course is not recommended for children, for lack of data; prosthetic material with viridans or S. bovis 6 wk, with gentamicin for the first 2 wk (Class I, LOE C). |
| Streptococci, relatively resistant to penicillin (MBC ≥0.2 µg/mL), includes enterococci. MBC in Table 7, MIC in its text (0.1–0.5 relatively resistant) | Penicillin G 200,000–300,000 U/kg/d divided every 4 h, up to 12–24 million U daily, or ampicillin 200–300 mg/kg/d divided every 4–6 h, up to 12 g daily; plus gentamicin 3–6 mg/kg/d divided every 8 h (Adult 3–5) for the first 2 wk, or the whole course for enterococci.Alternative: vancomycin plus gentamicin for enterococci; ampicillin plus ceftriaxone for aminoglycoside-resistant enterococci or an aminoglycoside-intolerant patient; ceftriaxone plus gentamicin, not for enterococci. Abiotrophia, Granulicatella or MIC >0.5: the enterococcal regimen (Class I, LOE C). Prosthetic material, MIC >0.1: gentamicin for all 6 wk (Class I, LOE C). Enterococci: always with infectious diseases (Class I, LOE C). Duration: native 4 wk; enterococcus 4–6 wk, 6 wk with vancomycin. Adult AHA 2026 consensus: ceftriaxone alone for viridans or S. gallolyticus with intermediate penicillin resistance; favors ampicillin plus ceftriaxone for E. faecalis. |
| Staphylococci, susceptible to ≤1 µg/mL penicillin G (rare), as printed | Penicillin G 200,000–300,000 U/kg/d divided every 4 h, up to 12–24 million U daily.This threshold and the next row's overlap in Table 7 and the statement does not reconcile them. Almost all staphylococci are highly resistant to penicillin (p 1502): penicillin G only on a qualified laboratory's susceptible result. Alternative: oxacillin or nafcillin 200 mg/kg/d divided every 4–6 h, up to 12 g/d; cefazolin 100 mg/kg/d divided every 8 h, up to 12 g daily, no type 1 penicillin allergy; vancomycin 40 mg/kg/d divided every 8–12 h, up to 2 g daily, at least 6 wk. Duration: native, oxacillin-susceptible 4–6 wk. |
| Staphylococci, resistant to 0.1 µg/mL penicillin G, as printed | Oxacillin or nafcillin 200 mg/kg/d divided every 4–6 h, up to 12 g/d, with or without gentamicin 3–6 mg/kg/d divided every 8 h (Adult 3–5 mg/kg) for 3–5 d.Overlaps the row above: see there. Gentamicin here may be considered (Class IIb, LOE C). ESC 2023 no longer recommends an aminoglycoside in native valve staphylococcal disease, for renal toxicity. Alternative: cefazolin 100 mg/kg/d divided every 8 h, up to 12 g daily, no type 1 penicillin allergy; vancomycin 40 mg/kg/d divided every 8–12 h, up to 2 g daily, if highly allergic to β-lactams, at least 6 wk. Duration: native, oxacillin-susceptible at least 4–6 wk (Class I, LOE A). |
| MRSA, resistant to 4 µg/mL oxacillin | Vancomycin 40 mg/kg/d divided every 8–12 h, up to 2 g daily.Duration: native at least 6 wk, with or without gentamicin for the first 3–5 d (Class I, LOE B). Methicillin-resistant staphylococci, including coagulase-negative: no nafcillin, oxacillin or cephalosporin, even if reported susceptible (AHA 2015). ESC 2023 native: vancomycin alone.Daptomycin: the sources conflict. AHA 2015 Table 7 offers it as the alternative, for right-sided endocarditis, maybe left-sided, and if vancomycin resistant or intolerant: 6 mg/kg every 24 h; under 6 y, 10 mg/kg. JCS 2026 Table 46: 6 mg/kg, for MRSA 6–10 mg/kg once daily, off-label for pediatric endocarditis in Japan. FDA label: not indicated for left-sided S. aureus endocarditis, poor outcomes in limited adult data; not studied in prosthetic valve endocarditis; avoid under 1 y; not indicated in children with renal impairment; pediatric indication is S. aureus bacteremia at 1–17 y, known endocarditis excluded from its trial, at 12 mg/kg 1–6 y, 9 at 7–11 y, 7 at 12–17 y, more than AHA 2015 at each age. Adult ESC 2023: 10 mg/kg with cloxacillin, ceftaroline or fosfomycin (IIb, C). AHA 2026: 8–12 mg/kg.What to do: left-sided or prosthetic, vancomycin stays first unless the organism is not susceptible (AHA 2015 Class I, LOE B). Daptomycin there is outside the label. This page's suggestion, not a label statement: decide it and its dose with infectious diseases. |
| All staphylococci, prosthetic material present | Add rifampin, doses in the unknown-organism rows, plus gentamicin for the first 2 wk.Duration: at least 6 wk. In a child now: AHA 2015 Table 7 and ESC 2023 (ESC Class I, LOE B) keep gentamicin for 2 wk; JCS 2026 says consider adding it; no pediatric source read drops it. Decide with infectious diseases; if used, weekly levels and creatinine. Adult AHA 2026 consensus: gentamicin risk outweighs benefit; no consensus on rifampin. Rifampin start: ESC 2023 after 3–5 days of effective therapy, once bacteremia has cleared; Adult AHA 2026 after 5–7 days, once cleared; AHA 2015 gives no timing. FDA rifampin label, postmarketing: with high-dose cefazolin, prolonged prothrombin time, can be severe or fatal; avoid at bleeding risk; if no alternative, monitor prothrombin time and coagulation tests, vitamin K as indicated. |
| Gram-negative enteric bacilli | Ceftazidime 100–150 mg/kg/d divided every 8 h, up to 2–4 g daily; cefepime, dose in the nosocomial row; cefotaxime 200 mg/kg/d divided every 6 h, up to 12 g daily; or ceftriaxone 100 mg/kg/d divided every 12 h or 80 mg/kg/d every 24 h, up to 4 g daily. Plus gentamicin or tobramycin 3–6 mg/kg/d divided every 8 h (Adult 3–5), or amikacin 15 mg/kg/d divided every 8–12 h, by susceptibility.Alternative: a broad-spectrum penicillin, such as piperacillin/tazobactam 240 mg/kg/d divided every 8 h, up to 18 g daily, plus an aminoglycoside. Duration: at least 6 wk (Class I, LOE C). Choose with infectious diseases, by susceptibility. |
| HACEK | Cefotaxime 200 mg/kg/d divided every 6 h, up to 12 g daily; or ceftriaxone 100 mg/kg/d divided every 12 h or 80 mg/kg/d every 24 h, up to 4 g daily; or ampicillin-sulbactam 200–300 mg/kg/d divided every 4–6 h, up to 12 g daily.Alternative, susceptible organisms: ampicillin 200–300 mg/kg/d divided every 4–6 h, up to 12 g daily, plus an aminoglycoside. Duration: 4 wk (Class I, LOE C). |
| Fungi: Candida, Aspergillus | Surgical resection plus amphotericin B 1 mg/kg/d over 3–4 h, or liposomal or lipid-associated 3–5 mg/kg/d as a single daily dose, with or without flucytosine 150 mg/kg/d orally divided every 6 h (100–150 in the text).FDA label: conventional amphotericin B not above 1.5 mg/kg; verify the product name and dose. Our reading: the 3–5 mg/kg here is liposomal or lipid only. Surgery with antifungals for most, Class I, LOE C. Flucytosine: Candida with a susceptible strain, Class IIb, LOE C, with blood levels (p 1504). Table 7 gives no duration: JCS 2026 Table 46 8 wk; Adult AHA 2026 6 wk. Alternative, if surgery cannot be done: amphotericin B then imidazole suppression, possibly lifelong. |
Levels and kidneys.
| Adult AHA 2026, consensus | JCS 2026, adult-framed | Pediatric |
|---|---|---|
| Planned 4–6 wk less the days given before surgery, at least 14 days after it; do not restart the clock. Culture or molecular positivity does not change the duration. Course finished, no active infection, negative tissue cultures: no more antibiotics. | Tissue culture positive: full course from the day of surgery. Negative: full course counting days before surgery. | AHA 2015 gives none. Russell 2013 gave 6 wk after surgery abstract. |
No pediatric schedule exists in anything read: echo interval, duration and culture timing are gaps.
Before any dose. FDA labels: each drug is contraindicated with known hypersensitivity to it; further lines only are listed.
| Situation | Agent | Children | Adult |
|---|---|---|---|
| Oral | Amoxicillin | 50 mg/kg | 2 g |
| Unable to take oral | Ampicillin | 50 mg/kg IM or IV | 2 g IM or IV |
| Cefazolin or ceftriaxone | 50 mg/kg IM or IV | 1 g IM or IV | |
| Allergic to penicillin or ampicillin, oral | Cephalexin | 50 mg/kg | 2 g |
| Azithromycin or clarithromycin | 15 mg/kg | 500 mg | |
| Doxycycline | <45 kg, 2.2 mg/kg; >45 kg, 100 mg | 100 mg | |
| Allergic, unable to take oral | Cefazolin or ceftriaxone | 50 mg/kg IM or IV | 1 g IM or IV |
ESC 2023 Table 6 prints the same child doses with maxima: amoxicillin and ampicillin 2 g; cefazolin or ceftriaxone 1 g; cephalexin 2 g; azithromycin or clarithromycin 500 mg.
| Question | One source | Another | Why it stays open |
|---|---|---|---|
| Pediatric against adult surgical classes: operate to prevent a first embolus? | Pediatric AHA 2015 Class III, LOE C: lack of proven benefit, long-term risks of valve replacement. JCS 2026 pediatric section: no clear data. | Adult JCS 2026 IIb, C (mobile >10 mm, low surgical risk). ESC 2023 IIb, B (≥10 mm, low surgical risk). ACC/AHA 2020 IIb, B-NR. AHA 2026 lists large vegetations (>1 cm), no class. | No pediatric study tests a size. Series report it: larger vegetation and embolic events, mitral OR 1.15 (1.02–1.31), aortic OR 1.08 (1.00–1.16), no unit printed (Wu 2023, Wu 2024); mobile >10 mm 30% vs 11% with and without neurologic complications, p=0.048 (Jacobwitz 2023); vegetation indexed to BSA HR 1.06 per mm/m² for death, left-sided (Khoo 2019). |
| Does surgery lower death in CHD? | Pediatric PAC3 2025: surgery is an independent predictor of lower in-hospital mortality Moderate / Strong. It rests on Yoshinaga 2008, 137 aged 1 month to 62 y: surgery OR 0.045 (0.003–0.70) in its stepwise model, univariate OR 0.38 (0.12–1.20), p=0.10. 14 deaths, 5 factors in the model; crude death 5 of 78 operated, 9 of 59 not. | Pediatric Elsisy 2026, 2108 CHD patients, after PAC3's search: in-hospital death 64 (10.1%) surgical vs 142 (9.6%) medical, p=0.72. | Elsisy is unmatched, from codes, and the surgical group was sicker, so equal rates there do not show surgery is neutral. PAC3 itself notes emerging adult CHD data with equal mortality. |
| Antibiotics after valve surgery | Adult AHA 2026: planned course less days given, at least 14 days after surgery; positivity does not change it. | JCS 2026: culture positive, full course from surgery; negative, full course counting days before surgery. | Not studied in children; table in Antibiotics and durations. |
| Pediatric regimen against the 2026 adult shift: staphylococcal prosthetic valve | Pediatric AHA 2015: add rifampin, plus gentamicin first 2 wk. JCS 2026 Table 46: consider adding; methicillin-susceptible at least 2 wk, methicillin-resistant 2 wk. ESC 2023: gentamicin 2 wk, Class I, LOE B. | Adult AHA 2026: gentamicin risk outweighs benefit; no consensus on rifampin. | ESC 2023 keeps it while citing a study in S. aureus prosthetic valve disease with no better outcome, and its nephrotoxicity. No pediatric update read. E. faecalis differs the same way: AHA 2015 penicillin or ampicillin plus gentamicin, ceftriaxone if intolerant; AHA 2026 favors ampicillin plus ceftriaxone. |
| Once-daily gentamicin in children | Pediatric AHA 2015 Class III, LOE C: insufficient experience in endocarditis. | ESC 2023 pediatric doses: 1 dose preferred for staphylococci, 1 or 3 for streptococci, 3 divided for enterococci and empiric treatment. | AHA 2015: no published outcomes in children with endocarditis. |
| TPV endocarditis: surgery or not | PAC3 2025: favor medical therapy if mild and stable Moderate / Strong. | Fox 2023 favors surgery abstract, unadjusted; sicker patients were operated on. | No controlled comparison. |
| Routine TEE before surgery | Wu 2023 abscess series screens routinely. | PAC3 2025 and Humpl 2003 keep it selective. | Neither is a controlled comparison. |
| RVOT gradient in Duke | PAC3 2025: minor criterion High / Strong. | Gafner 2025 proposes major: 11 cases vs 15 febrile controls abstract. | Small. |
Delay after stroke: the table in Stroke timing.
Tags: abstract authors' abstract only. textbook not the original study. PAC3 prints quality / strength; AHA 2026 prints no classes.
Tagged abstract where used. Results not read, so these may change.
Tagged textbook with edition, chapter and page: a textbook, not the original study. Paraphrased. No figure, table image or page render from any book is on this page; figure numbers are pointers to the book.